#genes

KRAS has been one of the most hard-to-hit targets in cancer research.

A gene called FOXR2 that is normally turned off is activated in at least 70% of cancer types. Can it be targeted with new treatments?

A new approach to prognosis looks to patients’ genomes for clues about how their cancer will behave.

There’s big news about metabolism from recent study findings that is shaking up our understanding of how metabolism changes with age.

A genomic study has uncovered molecular changes in tumors that may lead to dramatic and long-lasting responses to cancer therapy.

The benefits? Risk is assessed more rapidly and at a cheaper cost.

Damon Runyon alumnus and mentor Howard Y. Chang, MD, PhD, of Stanford University School of Medicine, receives the award in Molecular Biology

Researchers found that 80 percent of patient tumors had elevated levels of the protein GDF6, which correlated to the cancer’s aggressiveness

Some women with early-stage breast cancer may be able to cure the disease with hormone therapy alone.